Antidepressants and inflammatory bowel disease: A systematic review

Clinical Practice and Epidemiology in Mental Health

Volumn 2, Issue , 2006, Pages

  Mikocka Walus, Antonina A ^a   Turnbull, Deborah A ^a   Moulding, Nicole T ^a   Wilson, Ian G ^b   Andrews, Jane M ^c   Holtmann, Gerald J ^c  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF WESTERN SYDNEY   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; AZATHIOPRINE; CORTICOSTEROID DERIVATIVE; FLUOXETINE; MESALAZINE; MIRTAZAPINE; PARACETAMOL; PAROXETINE; PHENELZINE; PREDNISONE; SALAZOSULFAPYRIDINE; SERTRALINE;

CLINICAL STUDY; CLINICAL TRIAL; CROHN DISEASE; DEPRESSION; DRUG EFFICACY; ENTERITIS; HUMAN; INFORMATION PROCESSING; META ANALYSIS; PSYCHOLOGICAL ASPECT; PSYCHOSOMATIC DISORDER; PUBLICATION; RELIABILITY; REVIEW; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; ULCERATIVE COLITIS;

EID: 33750160203     PISSN: 17450179     EISSN: None     Source Type: Journal    
DOI: 10.1186/1745-0179-2-24     Document Type: Review

References (44)

1. Fort MM, Mozaffarian A, Stover AG, Correia Jda S, Johnson DA, Crane RT, Ulevitch RJ, Persing DH, Bielefeldt-Ohmann H, Probst P, Jeffery E, Fling SP, Hershberg RM: A Synthetic TLR4 Antagonist Has Anti-Inflammatory Effects in Two Murine Models of Inflammatory Bowel Disease. J Immunol 2005, 174:6416-6423.
2. Macfarlane S, Furrie E, Kennedy A, Cummings JH, Macfarlane GT: Mucosal bacteria in ulcerative colitis. Br J Nutr 2005, 93 Suppl 1:S67-72.
3. Plevy S: A STAT need for human immunologic studies to understand inflammatory bowel disease. Am J Gastroenterol 2005, 100:73-74.
4. Jowett SL, Seal CJ, Pearce MS, Phillips E, Gregory W, Barton JR, Welfare MR: Influence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study. Gut 2004, 53:1479-1484.
5. Addolorato G, Capristo E, Stefanini GF, Gasbarrini G: Inflammatory bowel disease: a study of the association between anxiety and depression, physical morbidity, and nutritional status. Scan J Gastroenterol 1997, 32:1013-1021.
6. Andrews H, Barczak P, Allan RN: Psychiatric illness in patients with inflammatory bowel disease. Gut 1987, 28:1600-1604.
7. Guthrie E, Jackson J, Shaffer J, Thompson D, Tomenson B, Creed F Psychological Disorder and Severity of Inflammatory Bowel Disease Predict Health-Related Quality of Life in Ulcerative Colitis and Crohn's Disease. Am J Gastroenterol 2002, 97:1994-1999.
8. Guthrie E: Psychological treatment in Crohn's disease. Journal of Psychosomatic Research 56 2004, 56:697.
9. Helzer JE, Chammas S, Norland CC, Stillings WA, Alpers DH: A study of the association between Crohn's disease and psychiatric illness. Gastroenterology 1984, 86:324-330.
10. Levenstein S, Prantera C, Varvo V, Scribano ML, Andreoli A, Luzi C, Arca M, Berto E, Milite G, Marcheggiano A: Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission. Am J Gastroenterol 2000, 95:1213-1220.
11. Porcelli P, Zaka S, Leoci C. Centonze S: Alexithyrmia in inflammatory bowel disease: a case-control study. Psychother Psychosom 1995:49-53.
12. Robertson DA, Ray J, Diamond I, Edwards JG: Personality profile and affective state of patients with inflammatory bowel disease. Gut 1989, 30:623-626.
13. Mittermaier C, Dejaco C, Waldhoer T, Oefferlbauer-Emst A, Miehsler W, Beier M, Tillinger W, Gangl A, Moser G: Impact of Depressive Mood on Relapse in Patients With Inflammatory Bowel Disease: A Prospective 18-Month Follow-Up Study. Psychosom Med 2004, 66:79-84.
14. Kurina LM, Goldacre MJ, Yeates D, Gill LE: Depression and anxiety in people with inflammatory bowel disease. Journal of Epidemiology and Community Health 2001, 55:716-720.
15. Jantschek G, Zeitz M, Pritsch M, Wirsching M, Klor HU, Studt HH, Rasenack J, Deter HC, Riecken EO, Feiereis H, Keller W: Effect of psychotherapy on the course of Crohn's disease. Results of the German prospective multicenter psychotherapy treatment study on Crohn's disease. German Study Group on Psychosocial Intervention in Crohn's Disease. Scand J Gastroenterol 1998, 33:1289-1296.
16. Keller W, Pritsch M, Von Wietersheim J, Scheib P, Osborn W, Balck F, Dilg R, Schmelz-Schumacher E, Doppl W, Jantschek G, Deter HC: Effect of psychotherapy and relaxation on the psychosocial and somatic course of Crohn's disease: main results of the German Prospective Multicenter Psychotherapy Treatment study on Crohn's Disease. J Psychosom Res 2004, 56:687-696.
17. Maunder RG, Esplen MJ: Supportive-Expressive Group Psychotherapy for Persons With Inflammatory Bowel Disease. Can J Psychiatry 2001, 46:622-626.
18. Schwarz SP, Blanchard EB: Evaluation of a psychological treatment for inflammatory bowel disease. Behav Res Ther 1991, 29:167-177.
19. von Wietersheim J, Scheib P, Keller W, Osborn W, Pritsch M, Balck F, Fritzsche K, Dilg R, Schmelz-Schumacher E: [The effects of psychotherapy on Crohn's disease patients-results of a randomized multicenter study]. Psychother Psychosom Med Psychol 2001, 51:2-9.
20. Kane S, Altschuler EL, Kast RE: Crohn's disease remission on bupropion. Gastroenterology 2003, 125:1290.
21. Kast RE: Crohn's disease remission with phenelzine treatment. Gastroenterology 1998, 115:1034-1035.
22. Kast RE, Altschuler EL: Remission of Crohn's disease on bupropion. Gastroenterology 2001, 121:1260-1261.
23. Walker EA, Gelfand MD, Gelfand AN, Creed F, Katon WJ: The Relationship of Current Psychiatric Disorder to Functional Disability and Distress in Patients with Inflammatory Bowel Disease. Gen Hosp Psychiatry 1996, 18:220-229.
24. Olden KW: The use of antidepressants in functional gastrointestinal disorders: new uses for old drugs. CNS Spectr 2005, 10:891-896.
25. Morgan V, Pickens D, Gautarn S, Kessler R, Mercz H: Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome. Gut 2005, 54:601-607.
26. Jackson JL, O'Malley PG, Kroenke K: Antidepressants and cognitive-behavioral therapy for symptom syndromes. CNS Spectr 2006, 11:212-222.
27. Jackson JL, O'Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K: Treatment of functional gastrointestinal disorders with anti-depressant medications: a meta-analysis. Am J Med 2000, 108:65-72.
28. Pace F, Molteni P, Bollani S, Sarzi-Puttini P, Stockbrugger R, Porro GB, Drossman DA: Inflammatory bowel disease versus irritable bowel syndrome: a hospital-based, case-control study of disease impact on quality of life. Scand J Gastroenterol 2003, 38:1031-1038.
29. Simren M, Axelsson J, Gillberg R, Abrahamsson H, Svedlund J, Bjornsson ES: Quality of Life in Inflammatory Bowel Disease in Remission: The Impact of IBS-LIke Symptoms ans Associated Psychological Factors. Am J Gastroenterol 2002, 97:389-396.
30. Best WP, Becktel JM, Singleton JW, Kern FJ: Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976, 70:439-444.
31. Walmsley RS, Ayres RC, Pounder RE, Allan RN: A simple clinical colitis activity index. Gut 1998, 43:29-32.
32. Alderson P, Green S, Higgins J: Cochrane Reviewers' Handbook 4.2.3. In The Cochrane Library Chichester, John Wiley & Sons, Ltd.; 2005.
33. Olsen O: The Cochrane Non-Randomised Studies Methods Group (NRSMG). [http://www.cochrane.dk/nrsmg/].
34. Ginsburg PM, Bayless TM: Managing Functional Disturbances in Patients with Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2005, 8:211-221.
35. Kast RE: Anti- and pro-inflammatory considerations in antidepressant use during medical illness: bupropion lowers and mirtazapine increases circulating tumor necrosis factor-alpha levels. Gen Hosp Psychiatry 2003, 25:495-496.
36. Kast RE, Altschuler EL: Bone density loss in Crohn's disease: role of TNF and potential for prevention by bupropion. Gut 2004,53:1056.
37. Kast RE: Evidence of a mechanism by which etanercept increased TNF-alpha in multiple myeloma: New insights into the biology of TNF-alpha giving new treatment opportunities-the role of bupropion. Leuk Res 2005.
38. Kast RE, Altschuler EL: Anti-apoptosis function of TNF-alpha in chronic lymphocytic leukemia: lessons from Crohn's disease and the therapeutic potential of bupropion to lower TNF-alpha. Arch Immunol Ther Exp (Warsz) 2005, 53:143-147.
39. Lichtenstein GR, Hanauer SB, Kane SV, Present DH: Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's disease. Inflamm Bowel Dis 2004, 10 Suppl 2:S2-10.
40. Talmadge J, Scott R, Castelli P, Newman-Tarr T, Lee J: Molecular pharmacology of the B-adrenergic receptor on THP-I cells. Int J Immunophormacol 1993, 15:219-228.
41. Lieb J: Remission of rheumatoid arthritis and other disorders of immunity in patients taking monoamine oxidase inhibitors. Int J Immunophormacol 1983, 5:353-357.
42. Gwee KA, Leong YL, Graham C, McKendrick MW, Collins SM, Walters SJ, Underwood JE, Read NW: The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999, 44:400-406.
43. Ringel Y, Drossman DA: Psychosocial aspects of Crohn's disease. Surg Clin North Am 2001, 81:231-52, x.
44. Kuiken SD, Tytgat GN, Boeckxstaens GE: The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol 2003, 1:219-228.